Although medications to treat alcohol and nicotine addiction continue to dominate the substance abuse treatment research pipeline, there are some promising therapies for opioid and cocaine addiction in development as well, states a report from New York-based GBI Research.
Moreover, the report finds that “various new approaches currently under investigation will see novel and first-in-class treatments, including vaccines, redefine the current arena.”
According to the business intelligence provider, 242 companies are currently marketing treatments for substance abuse, and alcohol dependence remains their top target. However, there also are 26 therapies for cocaine addiction and 21 therapies for opioid addiction in the research pipeline.
“A growing treatment pipeline and continued research and investment in this field reflects the fact that current therapies for those suffering from various drug addictions remain insufficient,” states a news release from GBI Research.